Companies Cryptocurrencies
Allena Pharmaceuticals Inc
Allena Pharmaceuticals Inc
Exchange: Nasdaq Global Select
IPO Date: 02/11/2017
CEO: Dr. Louis Brenner
Biotechnology Healthcare 🔗
  • ALNA
  • 0.123
  • 11042240
    market cap
  • 0.01050001
If you bought

shares of Allena Pharmaceuticals Inc (ALNA) on
You would have made
Old Price $12 Current Price $12

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Newton, Massachusetts and currently employs 45 full-time employees. The firm is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

Address: 1 Newton Executive Park Ste 202 Newton MASSACHUSETTS 02462

Stay updated.